雑誌文献を検索します。書籍を検索する際には「書籍検索」を選択してください。

検索

書誌情報 詳細検索 by 医中誌

Japanese

Effectiveness of DeVIC Chemotherapy for Recurrent Primary Central Nervous System Lymphoma Syuntaro TAKASU 1 , Toshihiko WAKABAYASHI 1 , Yasukazu KAJITA 1 , Norikazu HATANO 1 , Hisashi HATANO 1 , Takanori USUI 1 , Tomohiro KINOSHITA 2 , Jun YOSHIDA 2 1Department of Neurosurgery, Nagoya University School of Medicine 2First Department of Internal Medicine, Nagoya University School of Medicine Keyword: primary central nervous system lymphoma , recurrent , chemotherapy , DeVIC pp.789-794
Published Date 2000/9/10
DOI https://doi.org/10.11477/mf.1436901938
  • Abstract
  • Look Inside

Six cases with recurrent or refractory primary central nervous system lymphoma were treated with a new chemotherapeutic regimen “DeVIC (dexamethasone, VP16, ifosfamide, carboplatin)”.

Five recurrent cases had a remission period for an average of 18 months after initial treatment, but re-lapse occurred. One refractory case had no response after initial treatment. Then these 6 cases were treated with 1-3 courses of DeVIC chemotherapy at intervals of 4 weeks.

Two cases achieved complete remission, and 3 cases attained partial remission (response rate was 83%). One case showed no response after 1 course of DeVIC chemotherapy. However, in all cases re-relapse occurred 1-5 months after remission, and only 1 case is still alive. DeVIC chemotherapy produced a high response rate for recurrent central nervous system lymphoma, but re-relapse occurred after only a few months. The establishment of maintenance chemotherapy is re-quired.


Copyright © 2000, Igaku-Shoin Ltd. All rights reserved.

基本情報

電子版ISSN 1882-1251 印刷版ISSN 0301-2603 医学書院

関連文献

もっと見る

文献を共有